Cargando…

FUCA1 is induced by wild-type p53 and expressed at different levels in thyroid cancers depending on p53 status

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2017
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564410/ https://www.ncbi.nlm.nih.gov/pubmed/28731163 http://dx.doi.org/10.3892/ijo.2017.4077

Ejemplares similares

Corrigendum to ‘Understanding p53 functions through p53 antibodies’
por: Sabapathy, Kanaga, et al.
Publicado: (2019)

p53 directly regulates the glycosidase FUCA1 to promote chemotherapy-induced cell death
por: Baudot, Alice D., et al.
Publicado: (2016)

Corrigendum to “Prognostic Effect of Long Noncoding RNA NEAT1 Expression Depends on p53 Mutation Status in Cancer”
por: Idogawa, Masashi, et al.
Publicado: (2019)

Mutant P53 induces MELK expression by release of wild-type P53-dependent suppression of FOXM1
por: Bollu, Lakshmi Reddy, et al.
Publicado: (2020)

Corrigendum to ‘p53 balances between tissue hierarchy and anarchy’
por: Koifman, Gabriela, et al.
Publicado: (2019)

MUTYH, an adenine DNA glycosylase, mediates p53 tumor suppression via PARP-dependent cell death
por: Oka, S, et al.
Publicado: (2015)

Novel p53 target gene FUCA1 encodes a fucosidase and regulates growth and survival of cancer cells
por: Ezawa, Issei, et al.
Publicado: (2016)

Methylation-regulated ZNF545 inhibits growth of the p53-mutant KYSE150 cell line by inducing p21 and Bax
por: Fan, Yu, et al.
Publicado: (2021)

Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer
por: Sonego, Maura, et al.
Publicado: (2014)

Mutant p53 targeting by the low molecular weight compound STIMA‐1
por: Zache, Nicole, et al.
Publicado: (2017)

High-Level Expression of Wild-Type p53 in Melanoma Cells is Frequently Associated with Inactivity in p53 Reporter Gene Assays
por: Houben, Roland, et al.
Publicado: (2011)

The Stapled Peptide PM2 Stabilizes p53 Levels and Radiosensitizes Wild-Type p53 Cancer Cells
por: Mortensen, Anja Charlotte Lundgren, et al.
Publicado: (2019)

Corrigendum to: SOX6 suppresses the development of lung adenocarcinoma by regulating expression of p53, p21(CIPI), cyclin D1 and β‐catenin
Publicado: (2020)

p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients
por: Bourdon, Jean-Christophe, et al.
Publicado: (2011)

Elimination of wild-type P53 mRNA in glioblastomas showing heterozygous mutations of P53
por: Szybka, M, et al.
Publicado: (2008)

Interaction of p53 with the CCT Complex Promotes Protein Folding and Wild-Type p53 Activity
por: Trinidad, Antonio Garcia, et al.
Publicado: (2013)

Expression of wild-type p53-induced phosphatase 1 in diabetic epiretinal membranes
por: Xu, Jiping, et al.
Publicado: (2017)

Cell-cycle arrest and senescence in TP53-wild type renal carcinoma by enhancer RNA-P53-bound enhancer regions 2 (p53BER2) in a p53-dependent pathway
por: Xie, Haibiao, et al.
Publicado: (2021)

Mutant and Wild-Type Tumor Suppressor p53 Induces p300 Autoacetylation
por: Kaypee, Stephanie, et al.
Publicado: (2018)

Comparable radiation sensitivity in p53 wild-type and p53 deficient tumor cells associated with different cell death modalities
por: Li, Ping, et al.
Publicado: (2021)

Overexpression of RNF126 Promotes the Development of Colorectal Cancer via Enhancing p53 Ubiquitination and Degradation [Corrigendum]
Publicado: (2021)

20(S)-Ginsenoside Rg3 Promotes Senescence And Apoptosis In Gallbladder Cancer Cells Via The P53 Pathway [Corrigendum]
Publicado: (2019)

Inhibition by Differentiation‐inducing Agents of Wild‐type p53‐dependent Apoptosis in HL‐60 Cells
por: Noguchi, Kohji, et al.
Publicado: (1995)

p53-dependent and p53-independent anticancer effects of different histone deacetylase inhibitors
por: Sonnemann, J, et al.
Publicado: (2014)

The Inhibition of Autophagy Sensitises Colon Cancer Cells with Wild-Type p53 but Not Mutant p53 to Topotecan Treatment
por: Li, Dan-Dan, et al.
Publicado: (2012)

Mitochondrially targeted p53 or DBD subdomain is superior to wild type p53 in ovarian cancer cells even with strong dominant negative mutant p53
por: Lu, Phong, et al.
Publicado: (2019)

Elevation of effective p53 expression sensitizes wild-type p53 breast cancer cells to CDK7 inhibitor THZ1
por: Wang, Yueyuan, et al.
Publicado: (2022)

EGFR suppresses p53 function by promoting p53 binding to DNA-PKcs: a noncanonical regulatory axis between EGFR and wild-type p53 in glioblastoma
por: Ding, Jie, et al.
Publicado: (2022)

DDP-induced cytotoxicity is not influenced by p53 in nine human ovarian cancer cell lines with different p53 status.
por: De Feudis, P., et al.
Publicado: (1997)

Temperature sensitivity of human wild-type and mutant p53 proteins expressed in vivo.
por: Ponchel, F., et al.
Publicado: (1998)

p53/Lactate dehydrogenase A axis negatively regulates aerobic glycolysis and tumor progression in breast cancer expressing wild‐type p53
por: Zhou, Yao, et al.
Publicado: (2019)

Re-expression of the p53 Gene by Inhibiting the Mdm-2 Receptor in Wild-type p53 Tumors for the Treatment of Glioblastoma: A Mini Review
por: Ahmed, Syed Ijlal, et al.
Publicado: (2018)

Wild-type p53 is required for apoptosis induced by growth factor deprivation in factor-dependent leukaemic cells.
por: Zhu, Y. M., et al.
Publicado: (1994)

The Prognostic Impact of p53 Expression on Sporadic Colorectal Cancer Is Dependent on p21 Status
por: Kruschewski, Martin, et al.
Publicado: (2011)

Constitutive p53 heightens mitochondrial apoptotic priming and favors cell death induction by BH3 mimetic inhibitors of BCL-xL
por: Le Pen, J, et al.
Publicado: (2017)

Corrigendum to article “Quantitative proteomics reveals that long non-coding RNA MALAT1 interacts with DBC1 to regulate p53 acetylation’’
por: Chen, Ruibing, et al.
Publicado: (2021)

p53/TP53 Status Assessment in Gastroesophageal Adenocarcinoma
por: Boldrin, Elisa, et al.
Publicado: (2023)

Tumor Eradication by Wild-type p53-specific Cytotoxic T Lymphocytes
por: Vierboom, Michel P.M., et al.
Publicado: (1997)

Temperature sensitivity for conformation is an intrinsic property of wild-type p53.
por: Hainaut, P., et al.
Publicado: (1995)

Targeting Mdmx to treat breast cancers with wild-type p53
por: Haupt, S, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ubpp5l0mv2bgs1hputia2v4ck2